Dear Friend,

This year Democracy Now! is celebrating our 25th anniversary—that's 25 years of bringing you fearless, independent reporting. Since our very first broadcast in 1996, Democracy Now! has refused to take government or corporate funding, because nothing is more important to us than our editorial independence. But that means we rely on you, our audience, for support. Please donate today in honor of our 25th anniversary and help us stay on air for another 25 years. We can't do our work without you. Right now, a generous donor will even DOUBLE your gift, which means it’ll go twice as far! This is a challenging time for us all, but if you're able to make a donation, please do so today. Thank you and remember, wearing a mask is an act of love.
-Amy Goodman

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.


More Countries Delay Use of J&J Vaccine After Blood Clot Reports

HeadlineApr 14, 2021

The European rollout of the Johnson & Johnson vaccine has been delayed after regulators here in the U.S. moved to temporarily halt its use as reports of extremely rare blood clots were being investigated. South Africa also suspended its use of the Johnson & Johnson vaccine. Six women, aged 18 to 48, reported the clots after receiving the shot, and one has died. The number represents less than one in a million administered J&J shots in the U.S., and it’s not yet known if the condition is linked to the vaccine. What is known is the standard treatment of blood clots — heparin — is contraindicated for this reaction. President Biden sought to reassure the public the pause in J&J’s use would not hamper the White House’s vaccination goals.

President Joe Biden: “So, there is enough vaccine — that is basically 100% unquestionable — for every single, solitary American.”

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation